HWAM
SPRY icon

Hennion & Walsh Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Hennion & Walsh Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Buy
+175,614
New +$1.51M 0.04% 479

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Hennion & Walsh Asset Management's SPRY Position: Q2 2026 in Review

Hennion & Walsh Asset Management opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 175,614 shares worth $1.41M. The stake represents 0.04% of the portfolio and ranks #479 among its holdings.

209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Hennion & Walsh Asset Management held 175,614 shares of ARS Pharmaceuticals worth $1.41M as of Q2 2026.
  • ARS Pharmaceuticals was a new Hennion & Walsh Asset Management position in Q2 2026.
  • ARS Pharmaceuticals made up 0.04% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #479 holding.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.